Cas:28776-65-0 Poly(2,2-dimethyl-1,3-propylene succinate) manufacturer & supplier

We serve Chemical Name:Poly(2,2-dimethyl-1,3-propylene succinate) CAS:28776-65-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

Poly(2,2-dimethyl-1,3-propylene succinate)

Chemical Name:Poly(2,2-dimethyl-1,3-propylene succinate)
CAS.NO:28776-65-0
Synonyms:Butanoic acid, 4-oxo-, 3-hydroxy-2,2-dimethylpropyl ester;MFCD00134006;3-Hydroxy-2,2-dimethylpropyl 4-oxobutanoate
Molecular Formula:C9H16O4
Molecular Weight:188.221
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:261.9±20.0 °C at 760 mmHg
Density:1.1±0.1 g/cm3
Index of Refraction:1.451
PSA:
Exact Mass:188.104858
LogP:0.40

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like Butanoic acid, 4-oxo-, 3-hydroxy-2,2-dimethylpropyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Hydroxy-2,2-dimethylpropyl 4-oxobutanoate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Butanoic acid, 4-oxo-, 3-hydroxy-2,2-dimethylpropyl ester Use and application,MFCD00134006 technical grade,usp/ep/jp grade.


Related News: “From the new company, we’ll be able to provide customers with invaluable access to high-quality sterile fill and finish capacity, which is in huge demand globally,” Recipharm CEO Marc Funk said in a release. N-(2,3-Dichloro-phenyl)-N’-(4,5-dihydro-thiazol-2-yl)-hydrazine; hydrobromide manufacturers The growing use of biocatalysis in pharmaceutical chemistry promises to deliver on this need, while also offering substantial cost savings and faster time to market for urgently needed therapeutics. 4,6-Dimethyl-2-(2-pyrrolidin-1-yl-ethyl)-benzo[d]isothiazol-3-one suppliers Mene Pangalos, executive vice president, BioPharmaceuticals R&D, said: “The data being presented at EULAR add to the growing body of evidence for anifrolumab that demonstrate a compelling clinical profile with the potential to address significant unmet medical needs in this debilitating disease. tert-butyl (R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-2,2-dimethyloxazolidine-3-carboxylate vendor & factory.